Categories: News
      Date: Jan 26, 2009
     Title: Selexys Pharmaceutical Corporation and Cytovance® Biologics Sign Deal for the Process Development and cGMP Manufacture of  Selexys Pharmaceutical Corporation’s product HPL1 Monoclonal Antibody (Mab).

OKLAHOMA CITY, Okla. (26 Jan, 2009) – Cytovance® Biologics LLC , a biopharmaceutical contract manufacturing company specializing in mammalian cell culture, today announced the signing of a full service process development and manufacturing collaboration with Selexys Pharmaceutical Corporation.

“Selexys is pleased to announce the selection of Cytovance Biologics as our contract manufacturer for our lead drug candidate for Crohn’s disease. Cytovance brings substantial expertise in biologics manufacturing that will serve to advance our lead drug candidate into clinical development.” said Scott Rollins, President and CEO Selexys Pharmaceutical Corporation. ”We are very excited to join in this collaboration with Selexys on the development of their drug candidate.  It is great to be able to continue to combine expertise from two Oklahoma City based companies working so close together.” said Darren Head, President and CEO Cytovance Biologics. 

The Selexys Pharmaceutical Corporation project is to be executed in Cytovance’s multi-product Process Development and cGMP production facility in Oklahoma City over the next fifteen months.  The project team will be composed of members from both Oklahoma City based organizations working closely together.  The 44,000 sq. ft. facility meets the latest international regulatory standards and is custom-designed for efficient and cost-effective production.  Cytovance specializes in the execution of clinical and commercial production of antibody and recombinant protein products derived from cell culture and microbial fermentation at scales up to 500L (w/v) from both fed-batch and perfusion processes and 100L Disposable Bioreactors. 

About Selexys Pharmaceuticals
Selexys is a biopharmaceutical company focused on the development of antibody based therapeutics for inflammatory and thrombotic diseases.  The Selexys “Selectin Inhibition” platform has yielded 2 human/humanized antibody drug candidates focused on the treatment of Crohn’s and sickle cell disease. For more information on Selexys visit www.selexys.com.

Selexys Pharmaceutical Corporation Investor Contact:
Scott Rollins Ph.D.
President and CEO
Selexys Pharmaceuticals
srollins@selexys.com

About Cytovance Biologics
Cytovance Biologics is a biopharmaceutical contract manufacturing company specializing in the production of therapeutic proteins and antibodies from mammalian cell culture.  In addition to its cGMP manufacturing services, the company offers process development, cGMP cell banking and support services from its Oklahoma City, Okla. facilities. The company’s approach couples considerable client-side experience with the necessary technical and operational expertise to deliver precision science, agile manufacture, and reasonable business to that meet international regulatory standards and facilitate efficient completion of clinical development.  For more information on Cytovance, visit www.cytovance.com.

Cytovance Media and Investor Contact:
Molly S. McGlaughlin
VP Sales and Business Development
mmcglaughlin@cytovance.com